17.12.2014 VMS Deutschland Holdings GmbH  DE000A0LBFE4

DGAP-WpÜG: Takeover Offer;


 
Target company: MeVis Medical Solutions AG; Bidder: VMS Deutschland Holdings GmbH Dissemination of an announcement according to the German Securities Acquisition and Takeover Act (WpÜG), transmitted by DGAP - a service of EQS Group AG. The bidder is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Voluntary Takeover Offer ISIN DE000A0LBFE4 / WKN: A0LBFE Publication of the decision to make a voluntary takeover offer (freiwilliges Übernahmeangebot), pursuant to section 10 para. 1 in conjunction with sections 29 para. 1, 34 of the Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG) Bidder: VMS Deutschland Holdings GmbH Alsfelder Str. 6 64289 Darmstadt Germany registered with the commercial register at the local court (Amtsgericht) of Darmstadt, Germany, under registration number HRB 8654 Target: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany registered with the commercial register at the local court (Amtsgericht) in Bremen, Germany, under registration number HRB 23791 The shares of MeVis Medical Solutions AG (the 'Target') are listed in the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are traded in XETRA and in the over the counter market (Freiverkehr) in Frankfurt, Berlin, Dusseldorf, Munich and Stuttgart. VMS Deutschland Holdings GmbH (the 'Bidder') decided today to offer the shareholders of the Target to acquire their registered non par value shares of the Target (ISIN: DE000A0LBFE4/WKN: A0LBFE) by way of a voluntary public takeover offer (the 'Takeover Offer') against payment of an amount of EUR 17.50 in cash per share. The specific terms and conditions of the offer arise from the offer document for the Takeover Offer. The offer document and other information relating to the Takeover Offer will be published on the internet under http://www.variango1.de. The offer document will also be published in the Federal Gazette (Bundesanzeiger) by way of a notice (Hinweisbekanntmachung). Shareholders representing over 70 per cent. of the outstanding share capital of the Target (registered share capital of the Target minus treasury shares held by the Target) entered into separate agreements with the Bidder, according to which these shareholders irrevocably undertake to accept the Takeover Offer for all shares in the Target held by them under the conditions of the Takeover Offer. The Bidder currently does not have any shares of the Target. The Bidder intends to acquire all shares of the Target within the framework of the Takeover Offer, however, not less than 75 per cent. of the shares outstanding (registered share capital of the Target minus treasury shares held by the Target). Important notice: This notice is not an offer to buy or the solicitation of an offer to sell shares of the Target or other securities. The final terms and conditions of the intended Takeover Offer will be published in the offer document following the approval by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin). Investors and holders of shares of the Target are strongly recommended to read the relevant documents relating to the Takeover Offer, once they have been published by the Bidder, since they will contain important information. Investors and holders of shares of the Target can access these documents, once they have been published, on the website http://www.variango1.de. When the offer document has been published, it will also be available free of charge at a location, which is still to be determined, and be sent free of charge to investors and holders of shares of the Target upon request. The Takeover Offer will be issued exclusively under the laws of the Federal Republic of Germany, especially under the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG) and the Regulation on the Content of the Offer Document, Consideration for Takeover Offers and Mandatory Offers and the Release from the Obligation to Publish and Issue an Offer (WpÜG-Angebotsverordnung, WpÜG Offer Regulation). The Takeover Offer will not be executed according to the provisions of jurisdictions (including the jurisdictions of United States of America, Canada, Australia, and Japan) other than those of the Federal Republic of Germany. Thus, no other announcements, registrations, admissions or approvals of the Takeover Offer outside the Federal Republic of Germany have been filed, arranged for or granted. The shareholders of MeVis Medical Solutions AG cannot rely on having recourse to provisions for the protection of investors in any jurisdiction other than such provisions of the Federal Republic of Germany. Any contract that is concluded on the basis of the Takeover Offer will be exclusively governed by the laws of the Federal Republic of Germany and is to be interpreted in accordance with such laws. The Bidder has not approved the publication, sending, distribution, or dissemination of this notice or any other document associated with the Takeover Offer by third parties outside the Federal Republic of Germany. Neither the Bidder nor persons acting in concert with the Bidder within the meaning of section 2 para. 5 sentence 1 and sentence 3 WpÜG are in any way responsible for the compliance of the publication, sending, distribution, or dissemination of this notice or any other document associated with the Takeover Offer by a third party outside of the Federal Republic of Germany to any jurisdiction with legal provisions other than those of the Federal Republic of Germany. The release, publication or distribution of this notice in certain jurisdictions other than the Federal Republic of Germany may be restricted by law. Persons who are not resident in the Federal Republic of Germany or who are subject to other jurisdictions should inform themselves of, and observe, any applicable requirements. Darmstadt, Germany, 17 December 2014 VMS Deutschland Holdings GmbH End of WpÜG announcement The 17.12.2014DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 18,54 16,76 18,07 17,13 16,21 18,76 17,34
EBITDA1,2 9,18 7,60 8,25 5,97 4,77 7,99 3,99
EBITDA-Marge3 49,51 45,35 45,66 34,85 29,43 42,59
EBIT1,4 7,96 6,69 8,00 5,81 4,64 7,90 3,89
EBIT-Marge5 42,93 39,92 44,27 33,92 28,62 42,11 22,43
Jahresüberschuss1 5,62 7,17 8,07 5,70 4,55 7,79 4,92
Netto-Marge6 30,31 42,78 44,66 33,27 28,07 41,52 28,37
Cashflow1,7 7,32 5,52 6,55 2,89 9,13 4,86 5,85
Ergebnis je Aktie8 3,09 3,94 4,43 3,13 2,50 4,28 2,70
Dividende8 0,95 0,95 0,95 0,95 0,95 0,95 0,95
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
MeVis Med. Solutions
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0LBFE 25,000 Halten 45,50
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,42 10,26 1,02 7,62
KBV KCV KUV EV/EBITDA
2,55 7,77 2,62 10,61
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,95 0,95 3,80 19.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 27.05.2024 - 29.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,33% -8,38% -0,79% -30,17%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu VMS Deutschland Holdings GmbH  ISIN: DE000A0LBFE4 können Sie bei EQS abrufen


Medtech , A0LBFE , M3V , XETR:M3V